A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors.

Sadhna Shankar, Jim Vasselli, James Strauss et al.|Journal of Clinical Oncology|2018

Cited by 18